(Q34738050)

4 August 2017

1 reference

title

A modern rationale for the use of phenoxybenzamine in urinary tract disorders and other conditions (English)

1 reference

4 August 2017

1 reference

Alexis E Te

1

1 reference

4 August 2017

publication date

1 June 2002

1 reference

4 August 2017

published in

Clinical Therapeutics

1 reference

4 August 2017

volume

24

1 reference

4 August 2017

issue

6

1 reference

4 August 2017

page(s)

851-61; discussion 837

1 reference

Bladder Outflow Obstruction Treated with Phenoxybenzamine

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980003-0

7 January 2021

Phenoxybenzamine for benign prostatic obstruction review of 200 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980003-0

7 January 2021

A Placebo-controlled Double-blind Study of the Effect of Phenoxybenzamine in Benign Prostatic Obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980003-0

7 January 2021

Comparative study of therapeutic effect of dibenyline, finasteride, and combination drugs for symptomatic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980003-0

7 January 2021

Phenoxybenzamine in Prostatic Obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980003-0

7 January 2021

Management of neurogenic bladder dysfunction secondary to myelomeningocele

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980003-0

7 January 2021

Urodynamic studies in evaluating detrusor sphincter dyssynergia and their effects on the treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980003-0

7 January 2021

Phenoxybenzamine in neurogenic bladder dysfunction after spinal cord injury. II. Autonomic dysreflexia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980003-0

7 January 2021

Alpha-adrenergic blocker for posthernioplasty urinary retention. Prevention and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980003-0

7 January 2021

Prophylactic phenoxybenzamine in the prevention of postoperative retention of urine after vaginal repair: a prospective randomized double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980003-0

7 January 2021

Short-term morbidity and acceptability of 125iodine implantation for localized carcinoma of the prostate.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980003-0

7 January 2021

Transperineal 125iodine implantation for treatment of clinically localized prostate cancer: 5-year tumor control and morbidity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980003-0

7 January 2021

Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980003-0

7 January 2021

Temporal resolution of urinary morbidity following prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980003-0

7 January 2021

Phenoxybenzamine in the treatment of causalgia. Report of 40 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980003-0

7 January 2021

Complex regional pain syndrome (reflex sympathetic dystrophy and causalgia): management with the calcium channel blocker nifedipine and/or the alpha-sympathetic blocker phenoxybenzamine in 59 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980003-0

7 January 2021

Intravenous regional phenoxybenzamine in the treatment of reflex sympathetic dystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980003-0

7 January 2021

Adrenoceptor pharmacology: urogenital applications

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980003-0

7 January 2021

Carcinogenic properties of certain rubber additives

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980003-0

7 January 2021

10.1016/S0149-2918(02)80003-0

Identifiers

DOI

1 reference

4 August 2017

1 reference